Jane Street Group, LLC Kinnate Biopharma Inc. Transaction History

Jane Street Group, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$2.24 - $2.66 $78,146 - $92,799	-34,887 Reduced 45.15%	42,378 $112,000
Q4 2023 Feb 14, 2024	BUY	$1.07 - $2.5 $56,442 - $131,875	52,750 Added 215.17%	77,265 $183,000
Q3 2023 Nov 14, 2023	SELL	$1.38 - $3.31 $147,629 - $354,097	-106,978 Reduced 81.36%	24,515 $34,000
Q2 2023 Aug 14, 2023	BUY	$2.33 - $6.84 $268,141 - $787,160	115,082 Added 701.25%	131,493 $398,000
Q1 2023 May 15, 2023	BUY	$3.46 - $7.98 $13,293 - $30,659	3,842 Added 30.57%	16,411 $102,000
Q4 2022 Feb 14, 2023	BUY	$5.26 - $12.19 $66,112 - $153,216	12,569 New	12,569 $76,000
Q2 2022 Aug 16, 2022	BUY	$7.43 - $13.0 $86,455 - $151,268	11,636 New	11,636 $147,000
Q1 2021 May 18, 2021	SELL	$26.99 - $40.0 $163,262 - $241,960	-6,049 Closed	0 $0
Q4 2020 Feb 17, 2021	BUY	$36.35 - $45.25 $219,881 - $273,717	6,049 New	6,049 $241,000

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.